A rapid and inexpensive protocol to screen for third generation cephalosporin-resistant and non-fermenting Gram-negative rods directly in positive blood cultures.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 21 01 2021
revised: 03 05 2021
accepted: 07 05 2021
pubmed: 27 6 2021
medline: 3 11 2021
entrez: 26 6 2021
Statut: ppublish

Résumé

Third generation cephalosporins are frequently used in the first-line treatment of Gram-negative rod (GNR) bacteremia but are unsuitable in the case of extended-spectrum-beta-lactamase-producing Enterobacterales (ESBL-E) or non-fermenting GNR infections. The aim of this study was to develop and evaluate a simple and rapid two-test protocol involving oxidase and β-Lacta tests performed directly on positive blood culture broth as a preliminary screen for non-fermenting or third generation cephalosporins-resistant GNR. The diagnostic performance of this approach was evaluated on 294 bottles for the oxidase test and 267 bottles for the β-Lacta Test. The sensitivity and specificity of the oxidase test were respectively 93.1% and 100%, and the sensitivity of the β-Lacta Test for ESBL-E was 100% and the specificity 99.5%. This simple protocol, which can be implemented in all laboratories and performed in only 20 min, may be a valuable tool to optimize first-line antibiotic therapy for bacteremia.

Identifiants

pubmed: 34174522
pii: S0732-8893(21)00121-8
doi: 10.1016/j.diagmicrobio.2021.115428
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
Cephalosporins 0
Oxidoreductases EC 1.-
beta-Lactamases EC 3.5.2.6

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115428

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no competing interests.

Auteurs

Laurence Parmeland (L)

Centre Hospitalier Saint Joseph Saint Luc, 20 quai Claude Bernard, 69007 Lyon, France. Electronic address: lparmeland@chsjsl.fr.

Thomas Bourru (T)

Centre Hospitalier Saint Joseph Saint Luc, 20 quai Claude Bernard, 69007 Lyon, France.

Victoria Kyungu (V)

Centre Hospitalier Saint Joseph Saint Luc, 20 quai Claude Bernard, 69007 Lyon, France.

Nathalie Rousseau (N)

Centre Hospitalier Saint Joseph Saint Luc, 20 quai Claude Bernard, 69007 Lyon, France.

Marion Gleize (M)

Centre Hospitalier Saint Joseph Saint Luc, 20 quai Claude Bernard, 69007 Lyon, France.

Charlotte De Beauvoir (C)

Centre Hospitalier Saint Joseph Saint Luc, 20 quai Claude Bernard, 69007 Lyon, France.

Matthieu Pecquet (M)

Centre Hospitalier Saint Joseph Saint Luc, 20 quai Claude Bernard, 69007 Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH